CURRENT METHODS OF ENDOTHELIAL DYSFUNCTION ASSESSMENT AND THEIR POSSIBLE USE IN THE PRACTICAL MEDICINE

A review contains a description of the most common methods of evaluation and monitoring of "endothelial dysfunction" that are assessed in terms of their information content and applicability in the practice of medicine. The term "endothelial function" is interpreted primarily as a function of the regulation of capillary blood flow, carried out by the expense of the dynamic change of the phase of vasoconstriction and vasodilatation in vessels of resistive type (in accordance with the changing needs of cellular metabolism). Assessment of endothelial dysfunction is understood as a generalized indicator of the extent and nature of violations of the regulation of peripheral circulation. It includes an assessment of imbalances between endotheliumdependent vasoconstrictor and vasodilating factors or mismatch of the local and central regulation of capillary blood flow in response to various functional tests or other effects (eg, cold test, or test with local ischemia). All methods of endothelial dysfunction assessment in the survey are divided into invasive and non-invasive. The main feature of invasive methods lies in the direct effect on the endothelium of the coronary or other vessels by introducing into these vessels vasoactive substances such as acetylcholine. Response to the test (vasoconstriction or vasodilation) is evaluated by coronary angiography or by ultrasound. Non-invasive methods of the assessment of endothelial dysfunction or functions of regulation of the peripheral circulation are regarded as the most promising for widespread use. There are two basic methods that underlie functional tests: methods PAT (peripheral arterial tone) and PHG (polyhepatography). Assessment of endothelial dysfunction in many modern scientific researches is important. They are regarded as the causative factors of many different diseases. Such assessments can be useful in everyday medical practice. Assessment of endothelial function provides the clinician with critical information essential for a personalized selection of therapy. In particular, for taking into account the individual characteristics of the local and central regulatory system response of peripheral blood circulation in the various functional tests, or other effects.

1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.

2. Flammer A.J., Luscher T.F. Human endothelial dysfunction: EDRFs. Pflugers Arch. 2010;459:1005-13.

3. Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: EDCFs. Pflugers Arch. 2010;459: 1015-23.

4. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, thrombosis, and vascular biology. 2003;23:168-75.

5. Anderson T.J., Gerhard M.D., Meredith I.T., et al. Systemic nature of endothelial dysfunction in atherosclerosis. The American journal of cardiology. 1995;75:71B-74B.

6. Juonala M., Viikari J.S., Laitinen T., et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation. 2004; 110:2918-23.

7. Flammer A.J., Luscher T.F. Three decades of endothelium research: from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases. Swiss Med Wklv. 2010;140:wl3122.

8. Zeiher A.M., Drexler H., Wollschlaeger H., et al. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. Journal of the American College of Cardiology. 1989; 14:1181-90.

9. Edwards G., Feletou M., Weston A.H. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch. 2010;459:863-79.

10. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244–63.

11. Bazhenova L.N., Volodina N.N., Frolova N.P. Influence of preparation "Mexidol" on endothelial dysfunction in patients with chronic heart failure. Byulleten 'Eksperimental'noy Biologii i Meditsiny. 2006; suppl 1: 96-100. (In Russ.) [Баженова Л.Н., Володина Н.Н., Фролова Н.П. Влияние препарата "Мексидол" на эндотелиальную дисфункцию у больных с хронической сердечной недостаточностью. Бюллетень Экспериментальной Биологии и Медицины. 2006; приложение 1: 96-100].

12. Luscher T.E., Tschudi M.R., Wenzel R.R., Noll G. Endotheliale dysfunction und stiekstoffmoxid (NO, Nitric Oxide). Internist. 1997;38:411-9.

13. Petrishchev N.N., ed. Endothelial dysfunction. Pathogenetic importance and correction methods. SPb.: IITSVMA; 2007. (In Russ.) [Петрищев Н.Н., ред. Дисфункция эндотелия. Патогенетическое значение и методы коррекции. СПб.: ИИЦВМА; 2007].

14. Freedman J.E., Sauter R., Battinelli E.M. et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res. 1999; 84: 1416–21.

15. Dulak J., Jozkowicz A., Dembinska-Kiec A. et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:659-66.

16. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. The New England journal of medicine. 1986:315:1046-51.

17. Beltrame J.F., Crea F., Camici P. Advances in coronary microvascular dysfunction. Heart, lung & circulation. 2009;18:19-27.

18. Camici P.G., Crea F. Coronary microvascular dysfunction. The New England journal of medicine. 2007;356:830-840.

19. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation.1996;93:879-888.

20. Celermajer D.S., Sorensen K.E., Bull C., et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6):1468-74.

21. Petrenko T.E., Panin A.A., Volchanskiy E.I., Samohvalova V.V. Assessment of endothelial function in children and adolescents with hypertension according to Doppler ultrasound. Volgogradskiy NauchnoMeditsinskiy Zhurnal. 2009;24(4):50-1. (In Russ.) [Петренко Т.Е., Панина А.А., Волчанский Е.И., Самохвалова В.В. Оценка функции эндотелия у детей и подростков с артериальной гипертензией по данным ультразвуковой доплерографии. Волгоградский Научно-Медицинский Журнал. 2009;24(4):50-1].

22. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-9.

23. Parker B.A., Tschakovsky M.E., Augeri AL., et al. Heterogenous vasodilator pathways underlie flowmediated dilation in men and women. American journal of physiology. 2011;301:H1118-26.

24. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulation. Journal of the American College of Cardiology. 1995;26:1235-41.

25. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology. 2002;39:257-65.

26. Charakida M., Masi S., Luscher T.F., et al. Assessment of atherosclerosis: the role of flow-mediated dilatation. European Heart Journal. 2010;31:2854-61.

27. Harris R.A., Nishiyama S.K., Wray D.W., Richardson R.S. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010;55:1075-85.

28. Thijssen D.H., Black M.A., Pyke K.E, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. American Journal of Physiology. 2011;300:H2-12.

29. Mitchell G.F., Parise H., Vita J.A., et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension. 2004:44:134-9.

30. Philpott A.C., Lonn E., Title L.M., et al. Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. The American journal of cardiology. 2009;103:1610-5.

31. Huang A.L., Silver A.E., Shvenke E., et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2113-9.

32. Yeboah J., Crouse J.R., Hsu F.C., et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115:2390-7.

33. Thijssen D.H., Dawson E.A., Black M.A., et al. Heterogeneity in conduit artery function in humans: impact of arterial size. American Journal of Physiology. 2008;295:H1927-34.

34. Nohria A., Gerhard-Herman M., Creager M.A., et al. Role of nitric oxide in the regulashion of digital pulse volume amplitude in humans. J Appl Physiol. 2006;101:545-8.

35. Gori T., Dragoni S., Lisi M., et al. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. Journal of the American College of Cardiology. 2008;51:1953-8.

36. Levenson J., Simon A., Pithois-Merli I. Brachial arterial changes in response to wrist occlusion in normotensive and hypertensive men. The American journal of physiology. 1987;253:H217-224.

37. Spieker L.E., Luscher T.F., Noll G. ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans. J Cardiovasc Pharmacol. 2003;42:315-8.

38. Gori T., Parker J.D., Munzel T. Flow-mediated constriction: further insight into a new measure of vascular function. European Heart Journal. 2011 ;32:784-7.

39. Gori T., Muxel S., Damaske A., et al. Endothelial function assessment: flow-mediated dilation and constriction provide different and complementary information on the presence of coronary artery disease. Eur Heart J. 2012;33(3):363-71.

40. Yermolov S.Y., Shabrov A.V., Dobkes A.L. Poligepatografiya Hemodynamics Hepatitis. SPb.: Albee-SPb; 2007. (In Russ.) [Ермолов С.Ю., Шабров А.В., Добкес А.Л. Полигепатография Гемодинамика Гепатит. СПб.: Элби-СПб, 2007].

41. Litvinova L.S., Babak S.V., Kirienkova E.V. et al. Effect of liver function on the pharmacokinetics of βblockers in patients with coronary heart disease and comorbidity. Arkhiv Vnutrenney Meditsiny. 2013; 4 (12): 56-60. (In Russ.) [Литвинова Л.С., Бабак С.В., Кириенкова Е.В. и др. Влияние функции печени на фармакокинетику β-блокаторов у больных с ишемической болезнью сердца и сочетанной патологией. Архив Внутренней Медицины 2013;4(12):56-60].

42. Manasyan AG, Ermolov SY, Dobkes AL, et al. Comparative evaluation of polyhepatography, biopsy and elastography in determining the stage of liver fibrosis in patients with chronic liver disease. Klinicheskaya i Eksperimental'naya Gastroenterologiya. 2012;12:17-23. (In Russ.) [Манасян А.Г., Ермолов С.Ю., Добкес А.Л., и др. Сравнительная оценка полигепатографии, биопсии и эластографии в определении стадии фиброза печени у больных хроническими заболеваниями печени. Клиническая и Экспериментальная Гастроэнтерология. 2012;12:17-23].

43. Ermolov S.Iu., Shabrov A.V., Ermolova T.V., New approach to diagnostics and correction of portohepatic hemodynamics in patients with chronic liver diseases. Eksp Klin Gastroenterol. 2007;(4):82-7. (In Russ.) [Ермолов С.Ю., Шабров A.B., Ермолова Т.В., и др. Новые подходы к диагностике и коррекции нарушений портопеченочной гемодинамики. Клиническая и Экспериментальная Гастроэнтерология. 2007;4:13-6].

44. Yermolova T.V., Yermolov S.Y., Sologub T.V., Karev V.E. Violation portopechenochnoy hemodynamics and state nitrooksidergicheskoy system in patients with chronic viral hepatitis B and C. XVII Russian Congress "Hepatology today." Moscow, March 19-21, 2012. Moscow: ROPIP; 2012. P. 94. (In Russ.) [Ермолова Т.В., Ермолов С.Ю., Сологуб Т.В., Карев В.Е Нарушение портопеченочной гемодинамики и состояние нитрооксидергической системы у пациентов с хроническими вирусными гепатитами В и С. XVII Российский конгресс «Гепатология сегодня». Москва, 19-21 марта 2012. М.: РОПИП; 2012. С. 94].

45. Volkov V.S., Vysotsky N.N. Trotsyuk V.V., et al. Conjunctival biomicroscopy method was used for evaluation of the microcirculation (capillary blood flow evaluation software). Klinicheskaya Meditsina. 1976; 7: 115-9. (In Russ.) [Волков В.С., Высоцкий Н.Н., Троцюк В.В. и др. Метод конъюнктивальной биомикроскопии использовался и для оценки микроциркуляции (оценки обеспечения капиллярного кровотока). Клиническая Медицина. 1976;7:115-9].

46. Bohme H. Conjunctival microscopy for the diagnosis of changes in microcirculation. Its use as a routine method in the early diagnosis of vascular diseases. Z Gesamte Inn Med. 1972;27(15):633-42.

47. Kupriyanov V.V., Kolmykova V.I., eds. The study of microcirculation in experimental and clinical. Moscow: Molodaya Gvardiya; 1979. (In Russ.) [Куприянов В.В., Колмыкова В.И., ред. Изучение микроциркуляции в эксперименте и клинике. М.: Молодая Гвардия; 1979].

48. Francois J., Neetens A. Importance cliniqued el'angioscopie conjnctivale. Amm Oculist. 1967;2006:65663.